Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era

  • Isao Mitani
  • Diwakar Jain
  • Tammy M. Joska
  • Barbara Burtness
  • Barry L. Zaret
Article
  • 187 Downloads

Abstract

Background

Congestive heart failure (CHF) is among the most serious toxicities of doxorubicin, a potent cancer chemotherapeutic agent. Serial left ventricular ejection fraction (LVEF) monitoring during doxorubicin therapy for preventing CHF was proposed over 20 years ago. The current utility and cost-effectiveness of this approach in the present era are not known.

Methods and Results

Clinical and follow-up data of 265 patients with cancer (age, 53 ± 14 years; 76% women) undergoing doxorubicin chemotherapy with serial equilibrium radionuclide angiocardiography (ERNA) monitoring (≥2 studies) were analyzed retrospectively. Patients with a normal baseline LVEF (≥50%) and a 10% or greater point fall in LVEF to a final value of less than 50% during doxorubicin therapy were considered “at risk” for CHF (n = 41). Over 679 ± 426 days of follow-up, 7 patients (2.6%) had CHF develop and 90 (34%) died (all cancer-related deaths, with none due to CHF). A comparison of “at-risk” (n = 41 [15%]) and “low-risk” (n = 224 [85%]) groups showed a higher incidence of CHF (12% vs 0.9%, P < .0001), lower baseline LVEF (58% ± 8% vs 64% ± 8%, P < .0001), lower value for the lowest LVEF (42% ± 8% vs 57% ± 7%, P < .0001), and higher rate of cancer-related deaths (59% vs 29%, P = .0003) in the former despite similar cumulative doxorubicin dose (304 ± 124 mg/m2 vs 284 ± 110 mg/m2, P not significant). There were no differences in age, gender, cancer type, and co-morbidity. Cost analysis showed the overall cost of ERNA studies to be lower than the 1-year cost of caring for additional cases of CHF that would potentially be prevented by routine LVEF monitoring.

Conclusions

An incipient fall in LVEF detected on serial ERNA during doxorubicin therapy provides an appropriate and cost-effective approach for predicting and preventing impending CHF. Use of this approach was associated with a low incidence of CHF (2.6%) and no CHF-related mortality in this study. (J Nucl Cardiol 2003;10:132-9.)

Key Words

Doxorubicin cardiotoxicity equilibrium radionuclide angiocardiography left ventricular ejection fraction 

References

  1. 1.
    Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000;7:53–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Blum RH, Carter SK. Adriamycin. A new anticancer drug with significant clinical activity. Ann Int Med 1974;80:249–59.PubMedGoogle Scholar
  3. 3.
    Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988;15:15–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981;305:139–53.PubMedGoogle Scholar
  5. 5.
    Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987;19:817–28.PubMedCrossRefGoogle Scholar
  6. 6.
    Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol 1987;36:793–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076–86.PubMedGoogle Scholar
  8. 8.
    Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53:461–70.PubMedGoogle Scholar
  9. 9.
    Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133–9.PubMedGoogle Scholar
  10. 10.
    Black DJ, Livingston RB. Antineoplastic drugs in 1990. A review (part II). Drugs 1990;39:652–73.PubMedCrossRefGoogle Scholar
  11. 11.
    Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278–83.PubMedGoogle Scholar
  12. 12.
    Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302–14.PubMedCrossRefGoogle Scholar
  13. 13.
    Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873–9.PubMedGoogle Scholar
  14. 14.
    Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987;106:814–6.PubMedGoogle Scholar
  15. 15.
    Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109–18.PubMedCrossRefGoogle Scholar
  16. 16.
    van Royen N, Jaffe CC, Krumholz HM, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996;77:843–500.PubMedCrossRefGoogle Scholar
  17. 17.
    Callahan RJ, Froelich JW, McKusick KA, Leppo J, Strauss HW. A modified method for the in vivo labeling of red blood cells with Tc-99m: concise communication. J Nucl Med 1982;23:315–8.PubMedGoogle Scholar
  18. 18.
    Lee FA, Fetterman R, Zaret BL, Wackers FJ. Rapid radionuclide derived systolic and diastolic cardiac function using cycle-dependent background correction and Fourier analysis. In: Proceedings of Computers in Cardiology. IEEE Computer Society, Linkoping, 1985, pp. 443–6.Google Scholar
  19. 19.
    Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. Am Heart J 1998;135:S282–92.CrossRefGoogle Scholar
  20. 20.
    Konstam M, Dracup K, Baker D, et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction guideline. Clinical practice guideline. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service; US Department of Health and Human Services; 1994.Google Scholar
  21. 21.
    Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the studies of Left Ventricular Dysfunction (SOLVD) treatment trial. J Card Fail 1995;1:371–80.PubMedCrossRefGoogle Scholar
  22. 22.
    Schulman KA, Buxton M, Glick H, et al. Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial. Int J Technol Assess Health Care 1996;12:698–713.PubMedGoogle Scholar
  23. 23.
    Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Jain D, Zaret BL. Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity? J Nucl Med 1990;31:1965–9.Google Scholar
  25. 25.
    Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–7.Google Scholar
  27. 27.
    Bristow MR. Drug induced congestive heart failure. New York: Elsevier; 1980. p. 191–215.Google Scholar
  28. 28.
    Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827–34.PubMedGoogle Scholar
  29. 29.
    Minow RA, Benjamin RS, Lee ET, Gottlieb JA. Adriamycin cardiomyopathy-risk factors. Cancer 1977;39:1397–402.PubMedCrossRefGoogle Scholar
  30. 30.
    Kim YD, Lees DE, Lake CR, et al. Hyperthermia potentiates doxorubicin-related cardiotoxic effects. JAMA 1979;241:1816–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995;7:304–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 1994;28:1063–72.PubMedGoogle Scholar
  33. 33.
    Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997;4:30–5.Google Scholar
  34. 34.
    Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;4:15–21.CrossRefGoogle Scholar
  35. 35.
    Jain D, Wackers FJ, Wells L, Zaret BL. Reduced cardiotoxicity of liposomal doxorubicin (D99): a phase III single agent study in patients with metastatic breast cancer (MBC) [abstract]. J Am Coll Cardiol 1999;33(Suppl A):426A.Google Scholar
  36. 36.
    Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982;50:32–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978;62:857–64.PubMedGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2003

Authors and Affiliations

  • Isao Mitani
    • 1
  • Diwakar Jain
    • 1
  • Tammy M. Joska
    • 1
  • Barbara Burtness
    • 1
  • Barry L. Zaret
    • 1
  1. 1.Section of Cardiovascular Medicine, Cardiovascular Nuclear Imaging Laboratory, and Section of Medical Oncology, Department of MedicineYale University School of MedicineNew Haven

Personalised recommendations